STADA acquires rights to Nizoral brand from Johnson & Johnson

STADA Arzneimittel AG is further strengthening its position in branded over-the-counter healthcare products. The company says in a press release that it has acquired the rights to the medicated anti-dandruff shampoo Nizoral from Janssen Pharmaceutica NV (a member of the Johnson & Johnson family of companies).

The press release adds that the shampoo generated sales of approximately EUR 33 million in EMEA (Europe, Middle East, and Africa) in 2017.

– With Nizoral, STADA is adding a globally established brand to its portfolio that is highly recognized both by medical practitioners and customers, and which we believe has great potential for further growth. Together with head lice treatment Hedrin, Nizoral solidifies our competence in the hair and scalp product segment. The transaction is one of the largest in recent years and underlines our aspiration to be one of the leading providers of OTC products in Europe – emphasized STADA CEO Dr. Claudio Albrecht.

More than 50% of annual sales are generated in Russia, Italy, Great Britain, Poland, and the Middle East.

In addition to the umbrella brand Nizoral, STADA is also acquiring the local brands Nizoril, Nizorelle, Terzolin, Fungarest, Ketoderm, Oranozol, and Triatop. Nizoral cream for skin infections will be part of the purchase in Italy and Denmark only; in all other countries the cream will remain with Janssen Pharmaceutica NV and its affiliates, the press release says.

The anti-dandruff shampoo is marketed under the brand name Nizoral in Poland, Czech Republic, Slovakia and Hungary.

– We are excited to add Nizoral into our portfolio and to further expand our presence in the consumer healthcare market. In 2017 Poland achieved sales of EUR 2.90 million, Hungary of EUR 570.000, Slovakia of EUR 350.000 and Czech Republic of EUR 300.000. In the next few months we will be working together very closely with the seller in order to ensure a smooth transition in distribution – said Dr. Ronald Seeliger, General Manager of Hemofarm.

STADA Arzneimittel AG is a publicly-listed company with headquarters in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of generics, non-prescription OTC products and specialty pharmaceuticals, biosimilars in particular.

Worldwide, STADA is represented in about 30 countries with roughly 50 subsidiaries. Branded products such as Grippostad and Ladival are among the highest selling in their product categories in Germany.

In financial year 2017, STADA achieved adjusted Group sales of EUR 2,255.3 million, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 433.9 million and adjusted net income of EUR 195.6 million. As of December 31, 2017, STADA employed 10,176 people worldwide, the press release says.

STADA Grupa

Johnson & Johnson

Janssen Pharmaceutica NV

medicated anti dandruff shampoo Nizoral

head lice treatment Hedrin

Claudio Albrecht

OTC

Nizorelle

Terzolin

Fungarest

Ketoderm

Oranozol

Triatop

Nizoral cream for skin infections

Ronald Seeliger

CEO of Hemofarm

andti dandruff shampoo

medicated anti dandruff shampoo

STADA buys Nizoral rights from Johnson & Johnson

shampoo

shampoos

skin infection cream

anti dandruff products